Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. [electronic resource]
Producer: 20061108Description: 174-83 p. digitalISSN:- 0007-1048
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Arsenic Trioxide
- Arsenicals -- administration & dosage
- Ascorbic Acid -- administration & dosage
- Creatinine -- blood
- Female
- Humans
- Male
- Melphalan -- administration & dosage
- Middle Aged
- Multiple Myeloma -- blood
- Oxides -- administration & dosage
- Prospective Studies
- Recurrence
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.